• JANUARY 15, 2001

Ranbaxy net dips by 8%

Ranbaxy has reported a net profit of Rs 1,809 m on a turnover of Rs 17,418 m for the full year ended December 2000. While turnover has grown 12% the net profit has actually declined by 8%. However, for the fourth quarter ended 30th December 2000, net profit has gone up by 50% to Rs 483 m. Sales for the fourth quarter has increased from Rs 4,168 m to Rs 4,785 m.

(Rs m) FY00 FY01 Change
Sales 15,598 17,418 11.7%
Other Income 715 471 -34.1%
Profit after Tax/(Loss) 1,969 1,809 -8.1%
Net profit margin (%) 12.6% 10.4%  
No. of Shares (eoy) (m) 115.9 115.9  
Earnings per share 17.0 15.6  
P/E   41.4  

The disappointment for Ranbaxy, however, was the non-receipt of the milestone payment from Bayer, which the company has said will accrue in the first quarter of the current year. Besides, the company’s export of the generic cefuroxime axcetil has also run aground due to the litigation filed by Glaxo in the US courts. The coming year’s performance would be dependent on how soon the company’s US subsidiary breaks even.

The stock quotes at a price of Rs 646 which implies an earnings multiple of 41 times. The year 2000 saw the stock come off almost 50%. Whether 2001 would be any better remains to be seen.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407